News

The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs

Eli Lilly agreed to acquire three vaccine developers in deals worth up to nearly $4 billion combined, the company told The Wall Street Journal. Indianapolis-based Lilly has agreed to acquire Curevo, LimmaTech Biologics and Vaccine Co. Curevo is developing a shingles vaccine that Lilly believes could be as effective as the current standard but with reduced side effects, said Daniel Skovronsky, Lilly’s chief scientific and product officer.

(Bloomberg) -- US equity futures extended gains and Treasuries rallied as investors remained hopeful that the latest American strikes on Iran won’t derail talks to end the Middle East conflict. Most Read from BloombergNvidia CEO Urges Super Micro to Tighten Up on ComplianceTrump Doctor Visit Renews Health Scrutiny as 80th Birthday NearsTrump Says He’ll Announce Negotiated Deal With Iran ShortlyRubio Sees Good News Coming on Hormuz as Iran Talks ContinueUS, Iran Inch Toward Deal as Gaps Remain on

These players are seeing exciting results in clinical trials.

LLY's stock is still down year-to-date as AI-driven narratives have captured the bulk of investor attention and capital in 2026.

It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

Eli Lilly and Co (NYSE:LLY) last week reported late-stage weight loss data for retatrutide, which UBS analysts highlighted showed “solid strong weight loss efficacy” and were broadly in line with expectations ahead of further detail at the American Diabetes Association meeting. UBS...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Vanguard Dividend Appreciation Index Fund ETF Shares (NYSEARCA:VIG) is having a quieter year than its big-cap dividend-growth reputation suggests, with shares around $229 and a 5% year-to-date gain trailing the broader market. The 12-month picture is stronger at almost 17%, but the recent flattening tells you something important: VIG’s dividend-growth playbook is being squeezed ... VIG Investors: Watch the 10-Year Treasury Yield This Week—4.75% Is the Danger Line

The pharma giant is taking steps to expand its portfolio.

With a 5-year dividend growth rate of 15.23%, Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Dividend Growth Stocks to Buy and Hold for 3 Years. In a CNBC report published on May 21, Eli Lilly and Company (NYSE:LLY) said its experimental obesity drug, retatrutide, cleared a major late-stage clinical trial. The results […]

Go beyond the broad index and find which segment of healthcare best suits your portfolio needs now.

This breakdown considers whether Eli Lilly at around US$1,065 a share may still offer value or whether the best of the opportunity may already be behind it, with a focus on what the current price might imply. Over the short term, the stock has returned 6.0% over the past week and 15.6% over the past month. Year to date it is down 1.4%, and the 1 year return stands at 50.3%, with a very large gain over 5 years of around 7x. Recent headlines have centered on Eli Lilly's role in large scale...

Eli Lilly and Company (NYSE:LLY) is one of the best low risk stocks to buy in 2026. On May 21, Lilly’s Phase 3 TRIUMPH-1 trial evaluated retatrutide, an investigational once-weekly triple hormone receptor agonist (GIP/GLP-1/glucagon). The 80-week study involved 2,339 adults with obesity or overweight and at least one comorbidity, excluding diabetes. All doses met […]

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports

Eli Lilly (LLY) delivered impressive late-stage trial results for its newest weight-loss drug. UBS Global head of biotech research Michael Yee explains what this means for Novo Nordisk (NVO) and the future of the industry.

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the

Novo Nordisk (NYSE:NVO) has entered a partnership with OpenAI to apply artificial intelligence across drug discovery, manufacturing, and supply chain operations. The company is preparing a global rollout of the oral Wegovy weight loss pill after its US launch. Recent trial data for semaglutide and pipeline drugs such as Amycretin and CagriSema indicate further progress in obesity and metabolic disease treatments. Novo Nordisk is drawing fresh attention as it pairs an AI push with a growing...

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index advancing 0.8% and the State

Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.

Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of their body weight over 80 weeks at the highest dose. The results from the TRIUMPH-1 trial, the...

Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.

Eli Lilly (LLY) said Friday that a new analysis from two phase 3 trials showed that its GLP-1 pill F

(Updates with Novo Nordisk's response in the fourth paragraph.) Novo Nordisk's (NVO) Ozempic and

The findings could broaden the long-term opportunity for obesity and diabetes treatments.

While retatrutide may have the best weight loss efficacy to date, analysts hold concerns about its tolerability profile compared with best-seller, tirzepatide.

While Eli Lilly reigns supreme, Idea Pharma’s annual R&D ranking reveals which other large pharmas are on the rise — and which are stumbling.

Eli Lilly said on Thursday its retatrutide cleared a late-stage trial, helping patients lose an average 29% of their weight across 80 weeks.